FineImmu
About:
FineImmu develops solid tumor immunotherapy drugs.
Website: http://www.fineimmu.com/
Top Investors: Panacea Venture, Beijing Huafang Investment, Revel Ventures, Yabao Investment
Description:
FineImmu produces cell therapy drugs and immunodiagnostic products. The drug predicts the anti-tumor immune function of PD-1 and PD-L1 and the therapeutic effect of immune checkpoint inhibitors such as CTLA4. The company's contact modes are by phone and physical address.
Total Funding Amount:
90M CNY
Headquarters Location:
Guangzhou, Guangdong, China
Founded Date:
2018-01-01
Founders:
Number of Employees:
51-100
Last Funding Date:
2022-08-03
IPO Status:
Private
Industries:
© 2025 bioDAO.ai